US stocks: Fulcrum shares plummet over 50% after scrapping lead sickle-cell drug on FDA concerns
Economic Times
US stocks saw a significant drop as Fulcrum shares plummeted over 50% after the company scrapped its lead sickle-cell drug, pociredir, due to FDA concerns. The oral drug was being tested to treat sickle-cell disease, an inherited blood disorder. This development has impacted investor sentiment in the pharmaceutical sector US stocks: Fulcrum shares plummet over 50% after scrapping lead sickle-cell drug on FDA concerns. The oral drug pociredir was being tested for sickle-cell disease, an inherited
The oral drug, pociredir, was being tested to treat sickle-cell disease, an inherited blood disorder that can trigger pain, anemia and organ damage and reduce life expectancy.
(What's moving Sensex and Nifty Track latest market news, stock tips, Budget 2025, Share Market on Budget 2025 and expert advice, on ETMarkets. Also, ETMarkets.com is now on Telegram. For fastest news alerts on financial markets, investment strategies and stocks alerts, subscribe to our Telegram feeds .)
Subscribe to ET Prime and read the Economic Times ePaper Online.and Sensex Today.
Top Trending Stocks: SBI Share Price, Axis Bank Share Price, HDFC Bank Share Price, Infosys Share Price, Wipro Share Price, NTPC Share Price
Why Indian manufacturers may want the rupee to hit 100
Different eras, but current rupee slide has elements of 1991 crisis
Can a Rajan-style NRI dollar-deposit scheme save the rupee?
Iran war impact: Oil prices may be just one among many to pinch you
As West Asia boils, will Dubai’s loss be a GIFT for India?
Stock Radar: After a 24% correction, Max Healthcare breaks key resistance level; analysts see long-term potential
Choose your reason below and click on the Report button. This will alert our moderators to take action
Your Reason has been Reported to the admin.
15 Days Free: Unlock All ETPrime Exclusives, Market Tools & ePapers
It seems like you're already an ETPrime member with
Login using your ET Prime credentials to enjoy all member benefits
Log out of your current logged-in account and log in again using your ET Prime credentials to enjoy all member benefits.
Trump temper on H-1B visas is forcing Indians to do these things to stay put in US
What Adani’s US indictment means for India Inc’s overseas fundraising
Why veterans like Reliance, L&T are on acquisition spree? Aswath Damodaran has an answer.
Will China’s dollar bond sale in Saudi Arabia trump the US in financial world?
Huawei launches its own OS to compete with Google and Apple. But can it win beyond China?
Why a falling rupee is a better option for the economy
A list of top 20 momentum stocks that have delivered massive returns in one year
Get daily trade ideas from SEBI-registered research analysts.
Grow your wealth with stock ideas & sectoral trends.
All-in-one stock research with Stock Score, peer comparison & key signals.
Get to know where the market bulls are investing to identify the right stocks.
Check the score based on the company's fundamentals, solvency, growth, risk & ownership to decide the right stocks.
Analyze the market sentiments & identify the trend reversal for strategic decisions.
Ask your stock queries & get assured replies by ET appointed, SEBI registered experts.
Read the PDF version of ET newspaper. Download & access it offline anytime.
Read your daily newspaper in Digital View & get it delivered to your inbox everyday.
Manage your money efficiently with this weekly money management guide.
Read the PDF version of TOI newspaper. Download & access it offline anytime.
Explore the In-depth explanation of complex topics for everyday life decisions.
Get fitter with daily health insights committed to your well-being.
Manage your wealth better with in-depth insights & updates on finance.
Stay globally informed with exclusive story from New York Times.
Stream new documentaries from all across the world every day.